தங்கம் உயிரி தொழில்நுட்பவியல் நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article TAIPEI, Feb. 4, 2021 /PRNewswire/ Golden Biotechnology Corp.(TPEx:4132)( GoldenBiotech ), a leading Taiwanese biopharmaceutical company, announced that it has made two achievements for its Covid-19 new drug candidate Antroquinonol ® (HOCENA ®): receiving positive response after DMC review in Phase 2 clinical trial and signed first agreement in global licensing progress. GoldenBiotech receives in Jan. the Positive Response from DMC, an US FDA approved independent Data Monitoring Committee for its Phase 2 Covid-19 trial in the USA. The clinical trial data of the first set of patients in the Phase 2 trial were unblinded and reviewed by the DMC on the request of FDA. The review approved by the DMC as the positive response to the clinical trial with no need of modification on the trial and can proceed the following recruitment of the patients for the treatment of mild to moderate hospitalized Covid-19 patients. According to the FDA s guida

United statesSouth koreaSouth koreanCompany websiteGolden biotechnology corporationSee golden biotechnology corpGolden biotechnology corpKorea co ltdEmergency use authorizationGolden biotechnologyBiotechnology corporationஒன்றுபட்டது மாநிலங்களில்தெற்கு கொரியாதெற்கு கொரியன்நிறுவனம் இணையதளம்தங்கம் உயிரி தொழில்நுட்பவியல் நிறுவனம்